Cure8 research brief
FUT2-dependent intestinal fucosylation helps shape which gut microbes thrive and how the mucosa resists pathogens. For people with IBD, differences in FUT2 function and altered fucosylation may contribute to microbiome changes and intestinal inflammation—so this pathway could inform future personalized treatments.
Researchers studying the gut microbiome, immunologists, clinicians interested in IBD pathogenesis, and patients or advocates interested in microbiome-targeted therapies and genetics-informed approaches.
This review summarizes evidence that FUT2-driven α(1,2)-fucosylation of intestinal mucosal glycans is a central regulator of host–microbiota interactions.
It highlights mechanisms by which host factors (for example, IL-22 from ILC3s and enteric nervous system signals) control epithelial fucosylation, and how fucosylated glycans feed and select for beneficial microbes (notably Bifidobacterium and Bacteroides) while helping resist pathogens.
The review links dysregulated fucosylation and FUT2 secretor status to a range of human conditions, including inflammatory bowel disease and metabolic and infectious diseases, and discusses emerging therapeutic approaches aimed at modulating fucosylation—potentially personalized by FUT2 genotype.
The article is a narrative review (Frontiers in Microbiology) and the extracted content here is the article abstract; the brief above is grounded in that abstract rather than a full text appraisal.
This entry is based on the article abstract (narrative review). It summarizes current mechanistic and translational perspectives but does not report new clinical trial results. FUT2 secretor-status links are associative in many studies; therapeutic strategies discussed are emergent and may not yet be clinically validated.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
